{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:24:59Z","timestamp":1791440699753,"version":"4.3.3"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Erectile dysfunction (ED) is a highly prevalent condition with a variety of possible risk factors and\/or etiologies. Despite significant advances regarding ED pharmacological management, there are still insufficient responders to existing pharmacological treatments e.g., approximately 30% of patients are insufficient responders to phosphodiesterase type 5 inhibitors (PDE5-Is). It has been recently proposed that botulinum toxin A intracavernosally (IC) delivered could be effective in these patients. Data from a retrospective uncontrolled single center study of 47 ED patients, consecutively recruited, insufficient responders to existing pharmacological treatments e.g., PDE5-Is or IC PGE1 injections treated with IC abobotulinumtoxinA 250 or 500 U as free combination with their existing treatment have been analyzed. Response rate, according to the International Index of Erectile Function-Erectile Function domain score, 6 weeks following IC abobotulinumtoxinA in combination with prior pharmacological treatment, was 54%. Two patients have reported mild penile pain on injection or during the 3 days following injection. Therapeutic efficacy did not seem to be influenced by the etiologies and\/or risk factors for ED. Conversely, the less severe ED, the higher the response rate. Preliminary evidence for the therapeutical potential with acceptable safety of IC abobotulinumtoxinA as add-on therapy for ED not sufficiently responsive to standard therapy should be confirmed in randomized clinical trials.<\/jats:p>","DOI":"10.3390\/toxins11050283","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T10:52:51Z","timestamp":1558435971000},"page":"283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport\u00ae) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction\u2014Case Studies"],"prefix":"10.3390","volume":"11","author":[{"given":"Francois","family":"Giuliano","sequence":"first","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital, AP-HP, 104 bvd R. Poincare, 92380 Garches, France"},{"name":"Faculty of Medicine, Versailles Saint Quentin University, Paris Saclay, 78180 Montigny le Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Joussain","sequence":"additional","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital, AP-HP, 104 bvd R. Poincare, 92380 Garches, France"},{"name":"Faculty of Medicine, Versailles Saint Quentin University, Paris Saclay, 78180 Montigny le Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Denys","sequence":"additional","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital, AP-HP, 104 bvd R. Poincare, 92380 Garches, France"},{"name":"Faculty of Medicine, Versailles Saint Quentin University, Paris Saclay, 78180 Montigny le Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"NIH Consensus Conference (1993). Impotence. NIH Consensus Development Panel on Impotence. JAMA, 270, 83\u201390.","DOI":"10.1001\/jama.270.1.83"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1743-6109.2009.01624.x","article-title":"Anatomy, physiology, and pathophysiology of erectile dysfunction","volume":"7","author":"Gratzke","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1743-6109.2010.01778.x","article-title":"Definitions\/epidemiology\/risk factors for sexual dysfunction","volume":"7","author":"Lewis","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jsxm.2015.12.034","article-title":"Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015","volume":"13","author":"McCabe","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile Dysfunction: AUA Guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/j.1743-6109.2010.02062.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"7","author":"Montorsi","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Corbin, J.D. (2004). Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res., 16.","DOI":"10.1038\/sj.ijir.3901205"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jmhg.2006.08.007","article-title":"Non-responders to phosphodiesterase type 5 inhibitors: Is there a second chance?","volume":"3","author":"Hatzimouratidis","year":"2006","journal-title":"J. Men\u2019s Health Gender"},{"key":"ref_9","first-page":"407","article-title":"Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction","volume":"38","author":"Huang","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: A systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/340348a0","article-title":"Daedalus. High performance","volume":"340","author":"Jones","year":"1989","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.sxmr.2017.07.008","article-title":"Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction","volume":"6","author":"Ghanem","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int. J. Impot. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1743-6109.2007.00600.x","article-title":"Validation of the erection hardness score","volume":"4","author":"Mulhall","year":"2007","journal-title":"J. Sex. Med."},{"key":"ref_15","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/jsm.12335","article-title":"Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: Validation of an anchor-based treatment responder classification","volume":"10","author":"Yang","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/bmj.323.7313.596","article-title":"Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: Randomised, parallel group, double blind, placebo controlled trial","volume":"323","author":"Naumann","year":"2001","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0006-291X(90)92168-Y","article-title":"Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle","volume":"170","author":"Ignarro","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.1378650","article-title":"Nitric oxide: A physiologic mediator of penile erection","volume":"257","author":"Burnett","year":"1992","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1073\/pnas.052712499","article-title":"Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection","volume":"99","author":"Hurt","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.ijir.3901209","article-title":"Novel nitric oxide signaling mechanisms regulate the erectile response","volume":"16","author":"Burnett","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0006-291X(92)92305-H","article-title":"Tetanus toxin action: Inhibition of neurotransmitter release linked to synaptobrevin proteolysis","volume":"189","author":"Link","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/359832a0","article-title":"Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin","volume":"359","author":"Schiavo","year":"1992","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1023\/A:1022458322406","article-title":"Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: An historical overview of controversial issues","volume":"22","author":"Partoens","year":"1997","journal-title":"Neurochem. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1566-0702(02)00093-0","article-title":"Effects of botulinum toxin type A on the superior cervical ganglia in rabbits","volume":"102","author":"Kim","year":"2002","journal-title":"Auton. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuropharm.2013.02.012","article-title":"Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25","volume":"70","author":"Lawrence","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1476-5381.1973.tb08343.x","article-title":"Action of botulinum toxin on transmission from sympathetic nerves to the vas deferens","volume":"47","author":"Holman","year":"1973","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/wrr.12501","article-title":"Effect of botulinum toxin A on vasoconstriction and sympathetic neurotransmitters in a murine random pattern skin flap model","volume":"25","author":"Roh","year":"2017","journal-title":"Wound Repair Regen."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0022-5347(17)35539-8","article-title":"Antierectile role of the sympathetic nervous system in rats","volume":"150","author":"Giuliano","year":"1993","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.physbeh.2004.08.014","article-title":"Neural control of erection","volume":"83","author":"Giuliano","year":"2004","journal-title":"Physiol. Behav."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/00004872-199816121-00019","article-title":"Role of the sympathetic nervous system in human hypertension","volume":"16","author":"Grassi","year":"1998","journal-title":"J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/01.CIR.0000129252.96341.8B","article-title":"Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction","volume":"109","author":"Graham","year":"2004","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","article-title":"Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension","volume":"108","author":"Huggett","year":"2003","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00125-005-1798-z","article-title":"Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome","volume":"48","author":"Grassi","year":"2005","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1172\/JCI118235","article-title":"Sympathetic neural mechanisms in obstructive sleep apnea","volume":"96","author":"Somers","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jsxm.2016.10.005","article-title":"\u03b11A-Adrenergic Receptor Antagonism Improves Erectile and Cavernosal Responses in Rats With Cavernous Nerve Injury and Enhances Neurogenic Responses in Human Corpus Cavernosum From Patients With Erectile Dysfunction Secondary to Radical Prostatectomy","volume":"13","author":"Louro","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1055\/s-0028-1105971","article-title":"Autonomic complications following central nervous system injury","volume":"28","author":"Baguley","year":"2008","journal-title":"Semin. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.ju.0000173072.73702.64","article-title":"Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"174","author":"McVary","year":"2005","journal-title":"J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/HJH.0b013e32829baae7","article-title":"Sympathetic activity in major depressive disorder: Identifying those at increased cardiac risk?","volume":"25","author":"Barton","year":"2007","journal-title":"J. Hypertens."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/jsm.12164","article-title":"Standard operating procedures for neurophysiologic assessment of male sexual dysfunction","volume":"10","author":"Giuliano","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-5347(17)36062-7","article-title":"Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: A dose-finding study versus placebo","volume":"149","author":"Costa","year":"1993","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Johnson, R.M., and McGuire, E.J. (1981). Urogenital complications of anterior approaches to the lumbar spine. Clin. Orthop. Relat. Res., 114\u2013118.","DOI":"10.1097\/00003086-198101000-00017"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.ijir.3900292","article-title":"Evidence of sympathetic fibers in the male rat pelvic nerve by gross anatomy, retrograde labeling and high resolution autoradiographic study","volume":"9","author":"Giuliano","year":"1997","journal-title":"Int. J. Impot. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0090-4295(99)00099-0","article-title":"Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function","volume":"54","author":"Cappelleri","year":"1999","journal-title":"Urology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The International Index of Erectile Function (IIEF): A state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_51","unstructured":"(2019, April 22). Disport Therapeutic. Available online: https:\/\/ipsen.com\/websites\/IPSENCOM-PROD\/wp-content\/uploads\/sites\/18\/2018\/11\/08151628\/dysport-therapeutic-pm-Oct.24.2018_EN.pdf."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/5\/283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:53:54Z","timestamp":1760187234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/5\/283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["toxins11050283"],"URL":"https:\/\/doi.org\/10.3390\/toxins11050283","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]}}}